摘要
目的:通过随机、对照的临床研究,对疏血通治疗急性脑梗塞的有效性进行客观评价。方法:在发病24h之内就诊的108例急性脑梗塞患者随机分为疏血通组与对照组。疏血通剂量为6ml,静滴每日1次,连用14天;对照组丹参注射液250ml静滴,每日1次,连用14天。评定的终点指标包括脑卒中的临床神经功能缺损程度评分,血浆白细胞介素-6(IL-6)水平,肿瘤坏死因子-α(TNF-α)水平。结果:与对照组比较,疏血通24h内治疗者神经功能评分和IL-6、TNF-α水平下降显著(P<0.01),没有增加出血事件及其他副作用的发生。结论疏血通能显著降低急性脑梗塞患者血浆中炎性细胞因子IL-6、TNF-α的水平。
Objective: To assess the safety and efficacy of Shuxuetong in the treatment of acute cerebral infarction by randomized and controlled clinical trial. Methods.. 108 patients suffered acute cerebral infarction within 24 hours were randomly divided into two groups: Shuxuetong group and control group. Each patient in the Shuxuetong group was treated with Shuxuetong of 6 ml for 14 days,while those in the control group were given the Danshen250ml/d for14 days The end points included Clinically Neurological Deficits Scale of Stroke,the level of plasma TNF-α,IL-6. Results: Not only has the Neurological Deficits Scale of Stroke of Shuxuetong group decreased significantly compared with control group(P〈0.01), when Shuxuetong was used within24hours. The level of plasma TNF-α,IL-6 in the patients of Shuxuetong group was significantly decreased compared with that of the control group(P〈0.01). Conclusion: Shuxueton treatment could decrease the level of plasma TNF-α,IL-6 significantly and enhance tPA activity. Defibrase treatment is a safe and effective approach for acute cerebral infarction.
出处
《脑与神经疾病杂志》
2007年第6期445-446,共2页
Journal of Brain and Nervous Diseases
关键词
脑梗死疏血通TNF-α
IL-6
acute cerebral infarction Shuxueton fibrinogen TNF-α IL-6